Tempus AI, Inc. — Form 8-K
Filed November 18, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
AstraZeneca and Tempus AI amended their Master Services Agreement effective January 1, 2027, extending the collaboration through December 31, 2031 (with optional 6th-year extension to 2032). The renewal term commits AstraZeneca to a $200 million financial commitment (2027–2031) with minimum annual spending of $32 million, in addition to the original $220 million commitment for the initial term (through 2026), totaling $420 million over both periods. The amendment updates data licensing terms, lens access, a dedicated AstraZeneca team, and data protection obligations; many specific financial and operational details are redacted.
Why this rating
$420M total commitment is ~3.8% of Tempus's $11B market cap—meaningful but not transformational. Extension validates product-market fit and customer retention; recurring revenue is strategically valuable but represents expected business continuity rather than a shock.
See more from November 18, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.